Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

241
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
241
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

292
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
292
Cancer Vaccines01:30

Cancer Vaccines

347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adapting Sexual Behavior Survey Data to Parameterize an Agent-Based Model of Human Papillomavirus (HPV) Transmission.

Medical decision making : an international journal of the Society for Medical Decision Making·2026
Same author

Mammography screening and risk factor prevalence by sexual identity: A comparison of two national surveys.

Cancer·2025
Same author

Methodological Approaches for Incorporating Marginalized Populations into HPV Vaccine Modeling: A Systematic Review.

Medical decision making : an international journal of the Society for Medical Decision Making·2025
Same author

Human papillomavirus genotype-specific prevalence and infection risks: a 10-year population-based study from the United States.

Journal of the National Cancer Institute·2024
Same author

Population-level health impact of hypothetical waning 1-dose human papillomavirus vaccination and 2-dose mitigation strategies in a high cervical cancer burden setting.

Journal of the National Cancer Institute. Monographs·2024
Same author

Identifying Measures for Understanding and Addressing County-Level Disparities in Adolescent HPV Vaccination Coverage in North Carolina.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2024
Same journal

Genetically proxied inhibition of cholesterol-lowering drug targets and survival in HPV-positive and non-HPV driven head and neck cancer: a multicentre MR study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Retraction: Menstrual Factors, Reproductive History and Liver Cancer Risk: Findings from a Prospective Cohort Study in Chinese Women.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Optimizing the Uptake and Completion of the Cervical Cancer Screening Continuum: Opportunity Knocks, Including at Home.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Sex Differences in Cancer Stage at Diagnosis of Nonreproductive Solid Organ Tumors in the United States, 2015 to 2022.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Evaluation of the 4Kscore in EPIC: Reply.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Evaluation of the 4Kscore in EPIC: Letter.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.4K

Promise and Perils of Primary HPV Testing.

Jennifer C Spencer1,2, Cosette M Wheeler3,4,5

  • 1Department of Population Health, Dell Medical School, University of Texas at Austin, Austin, Texas.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
|August 1, 2024
PubMed
Summary
This summary is machine-generated.

Extending cervical cancer screening intervals to 8 years after a negative human papillomavirus (HPV) test is as safe as current methods. This finding supports longer screening schedules for better resource allocation in cancer prevention.

More Related Videos

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.4K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.3K

Related Experiment Videos

Last Updated: Jun 18, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.4K
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.4K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.3K

Area of Science:

  • Gynecology
  • Oncology
  • Public Health

Background:

  • Cervical cancer screening significantly reduces disease burden.
  • Optimizing screening methods and schedules remains a key research area.
  • Human papillomavirus (HPV) testing is an evolving primary screening modality.

Purpose of the Study:

  • To evaluate the risk of precancerous cervical disease 8 years after a negative HPV test.
  • To compare HPV testing intervals with the standard Pap test schedule.
  • To inform evidence-based adjustments to cervical cancer screening guidelines.

Main Methods:

  • Analysis of data from a randomized trial in British Columbia, Canada.
  • Integration of trial data with a provincial screening registry.
  • Risk assessment for cervical intraepithelial neoplasia grades 2 or worse.

Main Results:

  • The 8-year risk of precancerous disease after a negative HPV test was comparable to 3-year Pap testing.
  • Findings support extending screening intervals beyond the current 5-year recommendation for HPV-positive individuals.
  • Potential for resource reallocation to improve screening equity.

Conclusions:

  • Primary HPV testing allows for extended screening intervals.
  • Implementation challenges exist in fragmented healthcare systems.
  • Addressing barriers and improving health information systems are crucial for equitable HPV testing adoption.